Get the Stockscreener App
93.48
0.96%
0.89
After Hours:
93.50
0.02
+0.02%
Incyte Corp stock is traded at $93.48, with a volume of 2.50M.
It is up +0.96% in the last 24 hours and up +10.22% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$92.59
Open:
$92.7
24h Volume:
2.50M
Relative Volume:
1.30
Market Cap:
$18.25B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
21.25
EPS:
4.3988
Net Cash Flow:
$945.58M
1W Performance:
+2.41%
1M Performance:
+10.22%
6M Performance:
+49.19%
1Y Performance:
+26.12%
1-Day Range:
$92.06
$95.10
1-Week Range:
$84.02
$95.10
52-Week Range:
$53.56
$95.10
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
93.48 | 18.18B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Key metrics from Incyte Corporation’s quarterly data2025 Big Picture & Short-Term High Return Strategies - newser.com
Can Incyte Corporation (ICY) stock attract analyst upgradesQuarterly Market Summary & Real-Time Volume Analysis Alerts - newser.com
How Incyte Corporation stock responds to policy changesJuly 2025 Institutional & Real-Time Chart Pattern Alerts - newser.com
Is Incyte Corporation (ICY) stock undervalued by metricsBull Run & Free Expert Approved Momentum Trade Ideas - newser.com
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus
Can Incyte Corporation stock hit record highs againWeekly Trade Review & Expert Verified Stock Movement Alerts - newser.com
Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada
Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo! Finance UK
Incyte's (INCY) Hold Rating Reiterated at Truist Financial - MarketBeat
Incyte (INCY) Gains Exclusive Distribution Rights for Tafasitamab in Latin America - GuruFocus
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Transcend Capital Advisors LLC Makes New $437,000 Investment in Incyte Corporation $INCY - MarketBeat
Multi asset correlation models including Incyte CorporationMarket Risk Report & Fast Gain Stock Trading Tips - newser.com
Will Incyte Corporation (ICY) stock return to pre crash levels2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com
Can Incyte Corporation stock deliver sustainable ROELayoff News & Safe Entry Point Alerts - newser.com
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
RBC Capital Raises Incyte (INCY) Price Target to $84 | INCY Stoc - GuruFocus
Incyte (INCY) Rating Reiterated and Price Target Raised by Truis - GuruFocus
Wells Fargo Raises Incyte (INCY) Price Target to $97.00 | INCY S - GuruFocus
Incyte (INCY): Barclays Raises Price Target to $101 with Overwei - GuruFocus
Incyte Corporation (NASDAQ:INCY) Q3 2025 Earnings Call Transcript - Insider Monkey
Incyte Corporation $INCY Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus - Yahoo! Finance Canada
How Investors Are Reacting To Incyte (INCY) Surging Q3 Earnings and Promising Late-Stage Trial Data - Yahoo! Finance Canada
Incyte: Q3 Earnings Snapshot - Stamford Advocate
Incyte (NASDAQ:INCY) Hits New 12-Month HighWhat's Next? - MarketBeat
Incyte Walloped Third-Quarter Profit Views. Why Shares Fell. - Investor's Business Daily
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms - Benzinga
1 Growth Stock Under $100 to Buy Before It Soars - Yahoo Finance
Bank of America Securities Maintains a Buy on Incyte Corporation (INCY) - Insider Monkey
Incyte (INCY) Sees Strong Growth with Key Products and Raises Gu - GuruFocus
Why Incyte (INCY) Stock Is Trading Lower Today - Yahoo Finance
Incyte stock price target raised to $109 by BofA on strong Jakafi sales - Investing.com
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales - TradingView
Incyte Raises Sales Targets But Investors Aren’t Cheering - Finimize
Incyte (INCY) PT Raised to $109 at BofA Securities - StreetInsider
Incyte Q3 2025 slides: Revenue jumps 20% as product portfolio expands - Investing.com
Earnings call transcript: Incyte Q3 2025 beats forecasts, stock surges - Investing.com
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Incyte Outpaces Expectations And Raises Its Revenue Forecast - Finimize
Incyte (INCY) Boosts 2025 Revenue Forecast on Strong Product Dem - GuruFocus
Incyte Corporation (INCY) Q3 FY2025 earnings call transcript - Yahoo Finance
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Why Incyte Corporation (ICY) stock stays resilientWeekly Market Report & Growth Focused Stock Pick Reports - newser.com
Incyte Corp (INCY) Q3 2025 Earnings: EPS of $2.11 Beats Estimates, Revenue Surges to $1.37 Billion - GuruFocus
Incyte shares rise as third quarter results beat expectations, guidance raised By Investing.com - Investing.com South Africa
Incyte shares rise as third quarter results beat expectations, guidance raised - Investing.com
Incyte releases new data from Phase IIIb trial of Opzelura in dermatitis - The Pharma Letter
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):